Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Total Debt
Short-term and long-term borrowings combined.
Aktis Oncology, Inc.NASDAQ: AKTS
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt of $11.58M in Q1 FY2026
Q1 FY2026 total debt was $11.58M. Over 3 fiscal years it compounded at +86.7% a year.
Context
- Total debt amounted to 2.0% of total assets at the end of Q1 FY2026.
- Total debt increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 11.55M USD
- Year-over-year change
- -3.8%
- 3-year CAGR
- +86.7%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.55M | -3.8% |
| FY2024 | 2024-12-31 | 12.01M | -10.4% |
| FY2023 | 2023-12-31 | 13.4M | +655.0% |
| FY2022 | 2022-12-31 | 1.78M | — |
Total Debt vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 total debt of $11.58M is the 5th highest of the 6 companies compared; the peer median is $16.99M.
- Total debt amounts to 2.0% of total assets for AKTS, versus a peer median of 12.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $435.68M | +0.4% | +75.0% | 40.6% | |
| Mar 2026 | $36.51M | -2.6% | +45.3% | 16.8% | |
| Mar 2026 | $16.99M | -7.9% | -5.9% | 12.3% | |
| Mar 2026 | $15.34M | +68.2% | -26.6% | 2.4% | |
| Mar 2026 | $11.58M | — | +86.7% | 2.0% | |
| Sep 2026 | $10.26M | +155.6% | +136.6% | 2.0% | |
| Peer median (excluding AKTS) | $16.99M | +0.4% | +45.3% | 12.3% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.